Results 181 to 190 of about 131,858 (288)
Hyperglycemia, diabetes, and coronary microvascular dysfunction in INOCA. [PDF]
Mone P +9 more
europepmc +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 1514-1522, April 2025.
Takamasa Iwai +4 more
wiley +1 more source
ABSTRACT Insulin resistance is the biological phenomenon in which the human body's normal response to the metabolic hormone insulin is compromised. Insulin is a regulator of most of the essential metabolic steps in the body that control energy homoeostasis, so dysregulation leads to multiple diverse human diseases including, most prominently, Type 2 ...
Peter J. Little +12 more
wiley +1 more source
The association between coronary microvascular dysfunction and HbA1c in patients with unstable angina pectoris. [PDF]
Li K, Wang J, Liu S, Qi C.
europepmc +1 more source
The Endothelial CXCR Family in Vascular Health and Disease
ABSTRACT Endothelial cells (ECs) form the dynamic interface between blood and tissue, serving as key regulators of vascular homeostasis, inflammation, and repair. Among the molecular systems governing endothelial behavior, the C‐X‐C motif chemokine receptor (CXCR) family—originally characterized in immunology for its roles in leukocyte trafficking and ...
Zhiming Wu +4 more
wiley +1 more source
Prognostic significance of stress hyperglycemia ratio in coronary microvascular dysfunction among chronic coronary syndrome patients. [PDF]
Alifu J +12 more
europepmc +1 more source
ABSTRACT The scope, organization, and biological significance of innate immune functions across structural cell types remain poorly defined. To address these fundamental knowledge gaps, we analyzed experimental data of transcriptomes generated by our group and others.
Juanjuan Liu +22 more
wiley +1 more source
Myocardial Infarction With Nonobstructive Coronary Arteries With Coronary Microvascular Dysfunction Associated With Systemic Sclerosis: Case Report. [PDF]
Ohga Y +15 more
europepmc +1 more source
ABSTRACT It is estimated that a large proportion of drug candidates fail in human clinical trials, mainly because animal models cannot fully replicate human disease and because of differential responses to various medications between humans and animals.
Weiping Ding, Iqra Ilyas, Suowen Xu
wiley +1 more source
CAQ Corner: Immune‐mediated complications
Liver Transplantation, EarlyView.
Mary Thomson, John R. Lake
wiley +1 more source

